Charles Sande

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns.Lambisia AW Nyiro J Githinji G Katama EN Moraa E Mwita JM Mutunga M Maina G Bejon P Phan MVT Cotten M Dellicour S Ochola-Oyier LI Sande C Holmes EC Nyagwange J Agoti CN
Open Forum Infect Dis, (2026). 13:ofag084

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.Waweru G Nyakundi R Kutima B Owuor S Konyino G Gitonga J Lugano D Maina A Musyoki J Ochola L Omondi M Kariuki CK Ogongo P Mwachari C Shee F Agoti C Sande C Uyoga S Kagucia E Agweyu A Bejon P Scott JAG Warimwe GM Ochola-Oyier LI Nyagwange J
Viruses, (2025). 17:

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.Lambisia AW Katama EN Moraa E Mwita JM Gallagher K Mutunga M Nyale E Omungala J Mwanga M Murunga N Nyiro J Nyagwange J Sande C Bejon P Githinji G Dellicour S Phan MVT Cotten M Ochola-Oyier LI Holmes EC Agoti CN
BMC Glob Public Health, (2025). 3:80

Retaining African networks is urgent for global health.Bhiman JN Serwanga J Ugwu CA Vigan-Womas I Quashie PK Bhattacharya J Sande C Bonomo A Markey FB Awandare GA Garg PK Kaleebu P Happi C Rennergarbe A Woods C Kirchner J Aguilar AO Makar K Moore PL Giiser network
Trends Microbiol, (2025). 33:1150-1154

Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya.Musundi S Mwanga M Lambisia A Morobe JM Murunga N Moraa E Ndwiga L Cheruiyot R Musyoki J Mutunga M Guzman-Rincon LM Sande C Mwangangi J Bejon P Ochola-Oyier LI Nokes DJ Agoti CN Nyiro J Githinji G
Virus Evol, (2025). 11:veaf035

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano D Kutima B Kimani M Sigilai A Gitonga J Karani A Akech D Karia B Ziraba AK Maina A Lambisia A Omuoyo D Mugo D Lucinde R Owuor S Konyino G Newman J Bailey D Nduati E Githinji G Agoti CN Bejon P Scott JAG Agweyu A Kagucia W Warimwe GM Sande C Ochola-Oyier LI Nyagwange J
BMC Infect Dis, (2024). 24:1474

Inno4Vac Workshop Report Part 2: RSV-Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK.Waldock J Cox RJ Engelhardt OG Ascough S Osterhaus A Rimmelzwaan GF Ludlow M Tregoning JS McDonald JU Buchholz UJ Jeeninga RE Sande C Chiu C
Influenza Other Respir Viruses, (2024). 18:e70013

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.Terstappen J Hak SF Bhan A Bogaert D Bont LJ Buchholz UJ Clark AD Cohen C Dagan R Feikin DR Graham BS Gupta A Haldar P Jalang'o R Karron RA Kragten L Li Y Lowensteyn YN Munywoki PK Njogu R Osterhaus A Pollard AJ Nazario LR Sande C Satav AR Srikantiah P Stein RT Thacker N Thomas R Bayona MT Mazur NI
Lancet Infect Dis, (2024). 24:e747-e761

New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.Mwanga MJ Lambisia AW Morobe JM Murunga N Moraa E Ndwiga L Cheruiyot R Musyoki J Mutunga M Guzman-Rincon LM Sande C Mwangangi J Bejon P Ochola-Oyier LI Nokes DJ Agoti CN Nyiro J Githinji G
Emerg Infect Dis, (2023). 29:2376-2379

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.Mazur NI Terstappen J Baral R Bardaji A Beutels P Buchholz UJ Cohen C Crowe JE, Jr Cutland CL Eckert L Feikin D Fitzpatrick T Fong Y Graham BS Heikkinen T Higgins D Hirve S Klugman KP Kragten-Tabatabaie L Lemey P Libster R Lowensteyn Y Mejias A Munoz FM Munywoki PK Mwananyanda L Nair H Nunes MC Ramilo O Richmond P Ruckwardt TJ Sande C Srikantiah P Thacker N Waldstein KA Weinberger D Wildenbeest J Wiseman D Zar HJ Zambon M Bont L
Lancet Infect Dis, (2023). 23:e2-e21

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.Carbonell-Estrany X Simoes EAF Bont LJ Gentile A Homaira N Scotta MC Stein RT Torres JP Sheikh J Broor S Khuri-Bulos N Nokes DJ Munywoki PK Bassat Q Sharma AK Basnet S Garba M De Jesus-Cornejo J Lupisan SP Nunes MC Divarathna M Fullarton JR Rodgers-Gray BS Keary I Renosa MDC Verwey C Moore DP Noordeen F Kabra S do Vale MS Paternina-De La Ossa R Marino C Figueras-Aloy J Krilov L Berezin E Zar HJ Paudel K Safadi MAP Dbaibo G Jroundi I Jha R Rafeek RAM Pinheiro RS Bracht M Muthugala R Lanari M Martinon-Torres F Mitchell I Irimu G Pandey A Krishnan A Mejias A da Costa MSC Shrestha S Pernica JM de Carvalho FC Jalango RE Ibrahim H Ewa A Ensinck G Ulloa-Gutierrez R Miralha AL Lucion MF Hassan MZ Akhtar Z Aleem MA Chowdhury F Rojo P Sande C Musau A Zaman K Helena L Arlant F Ghimire P Price A Subedi KU Brenes-Chacon H Goswami DR Rahman MZ Hossain ME Chisti MJ Vain NE Lim A Chiu A Papenburg J Juarez MDV Senaratne T Arunasalam S Strand TA Ayuk A Ogunrinde O Tavares LVS Garba C Garba BI Dawa J Gordon M Osoro E Agoti CN Nyawanda B Ngama M Tabu C Mathew JL Cornacchia A Rai GK Jain A Giongo MS Paes BA
Front Pediatr, (2022). 10:1033125

Respiratory syncytial virus in young children: community cohort study integrating serological surveys, questionnaire and electronic health records, Born in Bradford cohort, England, 2008 to 2013.Zylbersztejn A Pembrey L Goldstein H Berbers G Schepp R van der Klis F Sande C Mason D Wright J Smyth R Hardelid P
Euro Surveill, (2021). 26:

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro JU Sande C Mutunga M Kiyuka PK Munywoki PK Scott JA Nokes DJ
Vaccine, (2015). 33:1797-801

Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples.Okiro EA Sande C Mutunga M Medley GF Cane PA Nokes DJ
J Clin Microbiol, (2008). 46:1659-62

Comparison of strain-specific antibody responses during primary and secondary infections with respiratory syncytial virus.Scott PD Ochola R Sande C Ngama M Okiro EA Medley GF Nokes DJ Cane PA
J Med Virol, (2007). 79:1943-50